AstraZeneca (NASDAQ:AZN) Stock Unloaded Rep. Bruce Westerman

Representative Bruce Westerman (R-Arkansas) recently sold shares of AstraZeneca PLC NASDAQ: AZN. In a filing disclosed on May 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in AstraZeneca stock on April 21st. The trade occurred in the Representative's "FISHER IRA" account.

Representative Bruce Westerman also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of UniCredit OTCMKTS: UNCRY on 4/21/2025.
• Sold $1,001 - $15,000 in shares of CSX NASDAQ: CSX on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Siemens Aktiengesellschaft OTCMKTS: SIEGY on 4/21/2025.
• Sold $1,001 - $15,000 in shares of GSK NYSE: GSK on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Charles Schwab NYSE: SCHW on 4/21/2025.
• Sold $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 4/21/2025.
• Sold $15,001 - $50,000 in shares of NVIDIA NASDAQ: NVDA on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Chevron NYSE: CVX on 4/21/2025.

AstraZeneca Stock Up 1.3%

NASDAQ:AZN traded up $0.85 on Friday, reaching $68.81. 3,742,544 shares of the stock traded hands, compared to its average volume of 5,176,170. The company has a market capitalization of $213.40 billion, a price-to-earnings ratio of 30.45, a PEG ratio of 1.42 and a beta of 0.40. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $87.68. The company's fifty day simple moving average is $70.46 and its 200 day simple moving average is $69.47.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, beating analysts' consensus estimates of $1.10 by $0.14. The business had revenue of $13.59 billion during the quarter, compared to analyst estimates of $13.71 billion. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. AstraZeneca's revenue was up 7.2% compared to the same quarter last year. During the same period last year, the business earned $2.06 EPS. Equities analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AZN has been the topic of a number of recent analyst reports. UBS Group raised shares of AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. BNP Paribas initiated coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target on the stock. Finally, Morgan Stanley initiated coverage on shares of AstraZeneca in a report on Wednesday, February 12th. They set an "overweight" rating on the stock. One research analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of "Buy" and a consensus price target of $88.00.

Hedge Funds Weigh In On AstraZeneca

A number of institutional investors and hedge funds have recently made changes to their positions in AZN. Tidal Investments LLC boosted its holdings in shares of AstraZeneca by 5.8% in the third quarter. Tidal Investments LLC now owns 6,649 shares of the company's stock worth $518,000 after buying an additional 362 shares during the last quarter. Nordea Investment Management AB purchased a new position in shares of AstraZeneca in the fourth quarter worth approximately $754,000. Diversified Trust Co boosted its holdings in shares of AstraZeneca by 5.8% in the fourth quarter. Diversified Trust Co now owns 5,630 shares of the company's stock worth $369,000 after buying an additional 309 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of AstraZeneca by 0.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 192,348 shares of the company's stock worth $12,603,000 after buying an additional 607 shares during the last quarter. Finally, Trust Co. of Toledo NA OH boosted its holdings in shares of AstraZeneca by 4.6% in the fourth quarter. Trust Co. of Toledo NA OH now owns 7,651 shares of the company's stock worth $501,000 after buying an additional 337 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company's stock.

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas' 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027. Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas' 4th Congressional District. He declared candidacy for the 2026 election. Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.